Business
Ondine commences first NHS Steriwave® pilot
Ondine commences first NHS Steriwave® pilot.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\n1 August 2023\n \nONDINE BIOMEDICAL INC.\n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\")\nOndine commences first NHS Steriwave® pilot\nMid Yorkshire Teaching NHS Trust will be using Ondine's nasal photodisinfection therapy prior to orthopaedic surgeries at Pontefract Hospital over a six-month pilot\n· Surgical site infections (SSIs) are the leading cause of readmission to hospital and three percent of patients who contract an SSI will die.[i]\n· SSIs are estimated to cost the NHS £700 million per year.[ii]\n· A patient with a surgical site infection will, on average, spend seven days more in hospital.[iii]\nMid Yorkshire Teaching NHS Trust has this week started the first UK pilot evaluation of Ondine Biomedical's Steriwave® nasal photodisinfection for the prevention of surgical site infections (SSIs). The six-month pilot will see 500 elective hip and knee surgery patients nasally decolonized using Steriwave prior to their surgery.\nSteriwave is already in use at a number of hospitals across Canada, including Vancouver General Hospital and The Ottawa Hospital, and has demonstrated significant improvement in post-surgical outcomes including lower rates of infection, reduced patient length of stay, fewer readmissions, and lower rates of antibiotic prescribing.[iv],[v],[vi]\nNasal decolonization is recommended by NICE to eliminate pathogens in a patient's nasal cavities, like MRSA, which are major causes of SSIs.[vii] A patient with a surgical site infection will, on average, spend 7 to 11 days more in hospital, significantly increasing costs and lengthening patients' recovery.[viii] Nasal mupirocin, an antibiotic, is usually used for nasal decolonization, however, there are serious concerns about its antimicrobial resistance rates which have been reported as high as 81%.[ix]\nDr Stuart Bond, Consultant Antimicrobial Pharmacist & Director of Innovation at Mid Yorkshire Teaching NHS Trust commented: \"We are very pleased to be the first NHS Trust in the UK to pilot this exciting, non-antibiotic method of preventing infections after surgery. Although infections after hip and knee surgeries are rare, we know that they lengthen patients' stay in hospital, complicate the recovery process, and cause significant pain and suffering. We look forward to sharing the res...